May 12, 2026
Blonde woman lying on bed — Getty Images(SeaPRwire) - About a century ago, surgeons operating on a woman observed small sac-like structures on her ovaries. Initially, they suspected these might be cysts, and since she also exhibited elevated levels of male hormones and infertility, the condition was named "polycystic ovary syndrome" (PCOS).At the time, this name seemed logical. However, what those physicians couldn't know was that the woman’s reproductive issues were just one manifestation of a much broader endocrine disorder. Over the past century, extensive research has shown that PCOS affects not only reproduction but also metabolism, cardiovascular health, and skin condition. Indeed, individuals with PCOS have significantly higher rates of Type 2 diabetes and cardiovascular disease, according to scientific findings.Yet, the presence of so-called cysts continued to hinder understanding of the true nature of the disease. “These were not actually true cysts,” explains Dr. Helena Teede, an endocrinologist and professor of women’s health at Monash University in Australia. The sacs consisted of eggs whose development had been halted due to widespread endocrine disruption. In the latest diagnostic guidelines, ovarian examination is no longer essential for diagnosis.Nevertheless, the perception that this condition primarily involves the ovaries has persisted. On May 12, a paper published in The Lancet announced the outcome of a movement to rename the disorder, which has gained momentum over more than a decade under Dr. Teede’s leadership: PCOS is now called polyendocrine metabolic ovarian syndrome, or PMOS. Advocates believe the change will expand research funding opportunities and clarify the disorder’s true scope for both patients and healthcare providers, who have long been confused by the misnamed cysts.Why does renaming from PCOS to PMOS matter?While scientific understanding of the disorder has evolved, awareness among patients and clinicians has lagged behind, says Rachel Morman, chair of the UK-based PCOS charity Verity and herself a patient with the condition. “There remained a very significant proportion of women with the condition who still believed they had ovarian cysts, and alarmingly, a large number of healthcare professionals shared that belief,” she notes.This confusion can lead to difficulties in receiving appropriate care and being taken seriously. “There’s no other medical condition I treat where nearly every person who walks into my office ends up in tears because they’ve finally been heard,” says Teede. “I keep boxes of tissues on hand.” Any endocrinologist would say the same, she adds. When patients finally receive a clear diagnosis and understanding, it brings immense relief.A National Institutes of Health meeting in 2012 brought together clinicians and researchers to consider a name change. Since then, surveys have been conducted with thousands of patients, and a global coalition of providers and advocates has debated whether a new name was necessary—and if so, what form it should take.The response from patient surveys was overwhelmingly in favor of change. The proposed new name, polyendocrine metabolic ovarian syndrome, seeks to reframe the condition as a complex hormonal imbalance impacting both metabolism and reproductive function.What will this new name mean for how PMOS is treated?“We hope it will transform clinical practice,” says Dr. Melanie Cree, a pediatric endocrinologist and professor at the University of Colorado Anschutz who contributed to the renaming effort. Historically, treatment has focused heavily on fertility and reproduction, often overlooking other systemic effects.“Most women do not receive proper metabolic screening,” Cree states. As a result, serious complications can go undetected for years.For example, in adolescents with PMOS, “cardiovascular disease begins very early,” Cree explains. Yet, when teenagers are diagnosed, they may only be prescribed birth control pills to manage symptoms—with little or no discussion or screening for metabolic disorders. This delay can lead to severe long-term health consequences.Viewing PMOS through a metabolic lens could open the door to treatments like GLP-1 medications, shifting away from purely reproductive-focused therapies, Cree suggests.It also means that research funding for the condition will no longer be restricted to sources focused solely on ovarian health. “Despite affecting approximately 170 million women of reproductive age and imposing a massive burden on health systems and economies worldwide, PCOS has received remarkably little investment in research,” Teede observes. “Reclassifying it opens pathways to greater evidence-based understanding and better treatment options.”How is PMOS diagnosed?Under current criteria, PMOS is diagnosed if a patient meets two out of three key indicators: (1) elevated levels of androgens (male hormones), (2) irregular menstrual cycles, and (3) high levels of anti-Müllerian hormone (AMH) in the blood, or the presence of many undeveloped follicles visible on ultrasound.“Sixty percent of women with the condition only need the first two criteria; ovarian assessment is unnecessary in their case,” Teede notes. For another 30–40%, either a blood test or ultrasound can confirm the diagnosis—and arguably, a blood test is more cost-effective and convenient than an internal ultrasound. She expects that over time, fewer people with PMOS will undergo unnecessary ultrasounds.What happens next?Over the next three years, the new terminology is expected to gradually permeate medical and scientific communities, culminating in the formal replacement of PCOS with PMOS in the International Classification of Diseases by 2028.The advocacy coalition anticipates resistance, particularly from businesses and influencers who have built branding around PCOS. “They stand to lose financially, and they have strong voices and platforms,” says Teede. “But we know from feedback within the community that women genuinely want this change.”For now, the team is celebrating their achievement. “All the endocrinologists are really excited,” Cree remarks. This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content. Category: Top News, Daily News SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.
More